Home CWBR
3.0532
  Price2.76%   -0.0868
 
loading
CohBar, Inc., a biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. Its lead MBT drug candidates include CB4209 and CB4211, which are in IND-enabling studies for the treatment of fatty liver disease, non-alcoholic steatohepatitis, obesity, and type 2 diabetes mellitus. The company is also developing Humanin, a mitochondrial-derived peptide to treat Alzheimer's disease, atherosclerosis, myocardial and cerebral ischemia, and type 2 diabetes mellitus; SHLP-6 for the treatment of cancer; and SHLP-2 to treat Alzheimer's disease and type 2 diabetes mellitus. CohBar, Inc. was founded in 2007 and is headquartered in Menlo Park, California.
Cap:    |  Volume (24h):